Harvard Pilgrim Health Care
Boston, Massachusetts, 02215, United States
NCT Number: NCT00790530
The purpose of this study is to evaluate the effectiveness of automated telephone outreach with speech recognition to improve diabetes care.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Boston, Massachusetts, 02215, United States
Randomly allocate a total of 1200 health plan members with diabetes to automated telephone outreach with speech recognition (ATO-SR; N = 600) or usual care (N = 600). The intervention is a series of three calls, using automated calls, originating from the health plan, using interactive speech recognition technology, spaced approximately 4-6 weeks apart, to encourage participants to fulfill the recommended testing (dilated eye examinations, glycated hemoglobin, LDL-cholesterol, microalbumin) that had not been performed received in the preceding year.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Automated Telephone Outreach with Speech Recognition
Usual Care
Time frame: 12-months following intervention
Time frame: one-year following intervention
Time frame: one year following intervention
Time frame: one-year following intervention
Looking for future studies?
Notify MeHarvard Pilgrim Health Care
Other
Acronym: ATO-SR-DM
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02821117
Diabetes Mellitus, Endocrine System Diseases
Hanover, Germany
View Trial DetailsNCT05186389
Body Weight, Diabetes Mellitus
Paris, France
View Trial DetailsNCT02593032
Cardiovascular Diseases, Diabetes Mellitus
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06186245
Acid-Base Imbalance, Acidosis
Lubbock, Texas, United States
View Trial Details